Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adapt Pharma Ltd.

www.adaptpharma.com

Latest From Adapt Pharma Ltd.

US FDA's Words Matter: Sharpless Says Injectable Naloxone OK For Community Distribution

The acting commissioner's statement is intended to clarify "persistent misunderstanding" about the label for the opioid overdose rescue medication's injectable formulation.

Neurology FDA

Purdue's Support For OTC Naloxone Would Continue In Bankruptcy

Bankrupt Purdue proposes continued funding for developing OTC naloxone product through firm to sell ‘millions of doses’ of the emergency opioid overdose product at low or no cost. Harm Reduction Therapeutics, which previously received funding from Purdue, has pushed back target date for NDA until early 2021 for its OTC naloxone nasal spray.
OTC Drugs Drug Approval Standards

Purdue's Opioid Rescue Drug Development To Continue Under A New Company

Purdue proposes continuing the development of nalmefene hydrochloride and other products under a new company that would provide the products at no or low cost.

Companies Research & Development

OTC Naloxone's Potential Overshadowed As FDA Priortizes Rx Generic Reviews

FDA appears committed to stemming opioid abuse by accelerating reviews of ANDAs for generics of overdose treatments but acceleration for making one of them, naloxone, available OTC is needed, too, says Michael Hufford, Harm Reduction Therapeutics CEO. "Relief that ... FDA is demonstrating its willingness to do everything that it can to accelerate these approvals," but "frustration that the public continues to be denied access to low cost naloxone," he says.
Prescription To Otc Switch OTC Drugs
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Adapt Pharma Ltd.
  • Senior Management
  • Seamus Mulligan, Chmn. & CEO
    David Brabazon, CFO
    Matt Ruth, Chief Commercial Officer
    Eunan Maguire, COO
    Fintan Keegan, CTO
    Ryan Loughlin, Dir., Drug Dev.
  • Contact Info
  • Adapt Pharma Ltd.
    Phone: 1 -6344-172
    45 Fitzwilliam Sq.
    Dublin 2,
    Ireland
Advertisement
Advertisement
UsernamePublicRestriction

Register